Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cipla Limited
In a year that has seen significant changes throughout the generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders. Meanwhile, companies lower down our ranking have enjoyed mixed fortunes, leading to a number of significant movements in this year’s Generics Bulletin Top 50.
Zydus is still on the lookout for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of generic Revlimid sales in Q2 led to a 24% drop over the previous quarter.
As family-led firms go through a churn in India, Lupin’s MD Nilesh Gupta speaks about adding value via adjacencies to the legacy business, building digital interfaces and a healthcare continuum for patients. In an interview with Scrip, he also emphasized Lupin promoters are neither interested in selling their own stake nor in acquiring that of Cipla’s promoters.
Zydus is still on the look out for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of Revlimid sales in Q2 led to a 24% drop over the previous quarter.
- Contract Research Organization-CRO
- Medical Devices
- Consulting Services
- Drug Delivery
- Generic Drugs
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Cipla Gulf FZ LLC
- Cipla Technologies LLC
- InvaGen Pharmaceuticals Inc.
- Mirren Pty, Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.